Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
Would you re challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another TKI?
Related Questions
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
How has your approach to utilizing MRD-guided therapy in previously untreated CLL changed since the FLAIR trial, particularly in choosing between continuous versus time-limited treatment?
Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?
How should one approach an incidentally found T-cell gene arrangement?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?
Would concurrent CRLF2/IgH rearrangement affect your treatment recommendations for an adult patient with Ph+ p190 high risk (Age>35, WBC >30) B-cell ALL that was started on induction therapy with ponatinib + blinatumomab?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
How would you manage an elderly patient with mild pancytopenia who refuses bone marrow biopsy and whose flow cytometry is suggestive of CMML/MDS?
